Plain-English translation of NCT05427084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
CANTOR SING is a research study testing whether , a medication already used to treat type 2 diabetes, can help reduce inflammation in the aorta—the large blood vessel that carries blood from the heart. Researchers believe this medication might have an additional benefit beyond lowering blood sugar: it may help calm down inflammation in the blood vessels of people with heart disease. This 6-month pilot study will compare the medication to a placebo (a dummy pill) to see if it actually works.
People with diabetes and heart disease often have ongoing inflammation in their blood vessels, which can lead to future heart problems. While this medication is already used to treat diabetes, doctors want to understand whether it can also help reduce this dangerous inflammation—a benefit that hasn't been fully studied before.
You likely qualify if…
You likely don't qualify if…
You will visit the Ottawa Heart Institute at the start of the study, then every 3 months for 6 months total. At each visit, you'll have blood tests and a physical exam. At the beginning and end of the study, you'll also have a special imaging scan (FDG PET with CT) to measure inflammation in your aorta. Throughout the 6 months, you'll take either the medication or a placebo pill once daily by mouth—neither you nor the researchers will know which one you're taking until the study ends.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Canada